Oxygen4Life™, Inc. has secured its CAGE Code, which gives the ability to sell our medical devices and products to U.S. government agencies, the military, and various organizations for the next 5-years.

FDA-Cleared Medical Devices and Wellness Solutions To Address and Detect Cardiovascular Diseases, Foot-Ulcers, Inflammatory Issues, and More.

We're Positioned For Massive Growth:

  • Two FDA 510(k) Cleared Class I & Class II Medical Devices. 
  • Registered Supplier For U.S. Government Agencies, VA, and Military.
  • ​Patented, CE Certified, Bluetooth Personal Wellness Device.
  • ​Patented Medical Food & Supplements Provided by Select Physicians.
  • ​Clinical and Evidence-Based Studies With Proof of Concept in Humans.

We Plan To Revolutionize Non-Invasive Healthcare

Personalized Precision: 

Our non-invasive FDA cleared Class II medical device provides precise and individualized assessments for the risk of cardiovascular diseases, abnormalities, and events such as heart attack and stroke¹ and chronic inflammation along with a personal cardio wellness device.

Support From Medical Practitioners:

Our products have been recommended by medical professionals around the world for over 20-years.

Evidence-based efficacy: 

Our products have been clinically shown to reverse vascular-plaque buildup, a key contributor to many deadly conditions. Reducing chronic inflammation and pain, resulting in improved quality of life and long-term health benefits.²

Highest Quality Products: 

Our plant-based, organic supplements & medical food are sustainably sourced, minimally processed, and COLD-PRESSED to create the highest-quality, unadulterated blend of essential fatty acids.³

ThermaLens™ - IRIS-XP™ Imaging System with AI Capabilities: 

FDA Class 1 - Medical Thermography System

ThermaLens™ - IRIS-XP™ systems integrate our proprietary high-resolution, infrared camera, and our artificial intelligence software for fast, accurate, and automatic disease detection.

This system can precisely measures a patient's heat signature to within a fraction of a degree, the use AI to cross-reference this data with our extensive database of verified medical cases.

This enables for the early detection of conditions such as:

Diabetic foot ulcers, circulatory diseases, neuropathy, chronic inflammation, peripheral artery disease, and more.

Reduce Amputations:

ThermaLens™ - IRIS-XP™ detects early signs of conditions like diabetic foot ulcers, reducing the need for amputations.

Fewer Hospital Visits:

With early and accurate detection, patients face fewer complications, reducing hospital admissions.

Cost-Efficiency:

Early interventions curtail prolonged treatments, offering substantial savings and an efficient use of resources.

Rates of Death:

By pinpointing conditions leading to amputations, we can play a pivotal role in decreasing mortality rates.

General System Benefits:
Seamless Integration: With PACS/EMR compatibility, ThermaLens™ - IRIS-XP™ can be effortlessly integrated into existing healthcare systems, ensuring a smooth workflow. 

Device Versatility: ThermaLens™ - IRIS-XP™ comes in various packages for a range of settings and environments – from large hospitals to mobile units.

​Expand Healthcare Offerings: Medical facilities can diversify their services, catering to a broader range of conditions.

​State-of-the-Art Technology: With the growing interest in thermography, ThermaLens™ - IRIS-XP™ is one of the first standardized medical thermography machines for large-scale production and professional use.
CUSTOM JAVASCRIPT / HTML

Introducing Brivanta™ - The Organic Medical Food

Brivanta™  is a plant-based, cold-pressed, and organic Essential Fatty Acid formulation, specifically designed as a medical food for those with an impaired "Delta-6 Desaturase Enzymatic Pathway".

Targeted Relief: Provides relief to those battling chronic inflammatory diseases due to a Delta-6 Desaturase Pathway impairment.

Physician Supervised: This medical food is exclusively available under the guidance of a licensed physician.

Patented & Proven: Patents granted in the United States and Canada, backed by over 20 years of evidence-based research and development.

​Easy Administration: Brivanta™, is an oil that remains liquid even at cold temperatures, and should be stored in the fridge to prevent rancidity. It comes with a small measuring spoon for easy and precise dosing.

As we age, this Delta-6 Desaturase enzymatic pathway is known to become impaired.⁷ This impairment has been linked to multiple chronic inflammatory diseases and immune-deficiencies.

With over two decades in development, Brivanta™ offers a targeted dietary management approach for chronic inflammation. Today, the modern diet unknowingly may cause chronic inflammation leading to ill-health.⁶⁷ 

Inflammatory response starts with the Delta-6 Desaturase enzymatic pathway.⁹

People Are Experiencing Results:

Results speak for themselves, and our mission is to help even more people.

Use the arrows to cycle testimonials
CUSTOM JAVASCRIPT / HTML
(These Testimonials For Oxygen4Life Supplements, Not For The Medical Food Brivanta™)

Solutions We Provide To The Market:

Patented Supplements 
and Medical Food

Medical Technologies for Clinical & Consumer Use

Wholesale, Resell, and Medical Partnerships

Partnership Opportunities:

E-commerce and Multi-Channel Marketing 

It's never been easier to reach our target audiences and drive online E-commerce sales.

Doctors, Physicians, and Medical Practitioners

Use our products and medical devices to help your patients and increase sales.

Wholesale, Resell, and White Labeling

Become a distributor and receive the rights to re-sell our products.

Sales Representative Opportunities

Become a certified sales rep. for Oxygen4Life™, Inc. products and devices.

Doctor Testimonials:

Our products are used and recommended by medical professionals around the world

- Robert L. Kagan (Nuclear Medicine Specialist)

"I previously wrote you about the remarkable cause / effect relationship in reversing plaque volume in a (smoking) patient taking conventional treatment (i.e. statins, aspirin, Co-Q10, etc.). In reading over the patients scans, I have never seen such a remarkable result. When he [the patient] stopped taking PEOs, the plaque came back!"

- Brian N. Vonk, M.D. (Board certified: Internist, Cardiologist, Radiologist)

"Impeccable research and novel insights of sheer genius. This knowledge is priceless for your future health.”

- Kelvin Lindgren, M.D. (Otolaryngologist/ENT)

"Thanks to you and your discovery of PEOs, he (the patient) is back to playing golf, walking the course. All medical professionals need to know about the science behind this product."

- Clive Fields, M.D. (Family Practice)

"The most thoroughly researched nutritional anticancer program that I have ever seen. My patients have also noticed their energy levels have skyrocketed..."

- Angelo A. Della Pietra, M.D., D.O. (Family & Integrative Medicine)

"Physicians and their patients around the world owe you a big ‘thank you.’... I am strongly recommending this information to all my patients.”

Company Growth and Milestones:

Jan. 13, 2023

Day of Launch with DealMaker Securities LLC

Jan. 15, 2023

Minimum requirement of raising $10,000.20 completed

Jan. 19, 2023

Founder & CEO Mike Maunu presents Health Webinar to members of the 'Silicon Valley Health Institute'

Feb. 20, 2023

Company launches their 100,000 Shares of Class B Common Stock with their Give-A-Way Promotion

April 4, 2023

(End of Stock Give-A-Way Promotion)
Shares Given Were Class B Common
1st: Nate Thorne - 50,000 shares
2nd: Troy Vanderhoof  - 30,000 shares
3rd: Andrew Croot - 20,000 shares

May 5, 2023

Nate Thorne has been added to the  board of executives for Oxygen4Life™, Inc. as the new Chief Financial Officer (CFO)

June 29, 2023

Oxygen4Life™, Inc. presented and exhibited it's products at the Global Capital Network event in Newport Beach, CA.

August 1, 2023

Approved by SAM.gov, the first step to providing our products and services to government agencies and Veterans Assistance.

August 14th, 2023 - 
Oxygen4Life™, Inc. obtains its CAGE Code

Oxygen4Life™, Inc. NOW has the ability to sell its products to U.S. government agencies and military branches for the next 5-years.

Whitepapers and Evidence:

³Adulterated vs un-adulterated Omegas

Distinguish between the effects of unadulterated (natural) forms of parent omega-6 (Linoleic Acid "LA"), versus adulterated (chemically altered) forms is vital to truly understand the beneficial effects of essential fatty acids on the  cardiovascular system. 

²The IOWA Study

Long-term PEO supplementation was evaluated in thirty-four (34) subjects. Results showed the average improvement in arterial flexibility was a 9 year improvement, meaning the average subject using PEOs had the vascular system of someone almost a decade younger.

Private Clinical Study

Lead patient had a cardiac calcium score decrease by 20% and the only thing it could be attributed to was the PEOs he started taking for cancer prevention. (Study from a radiology practice which provides CT, MRI, PET and Ultrasound examinations. )

Veteran Diabetic Foot Ulcer (DFU) Epidemic: 
A U.S. Department of Veterans Health Administration (VHA) Hyperbaric Oxygen Therapy (HBOT) Services Review

The increase in the Worldwide Diabetic Patient population at risk for Lower Limb Amputation (LLA) is growing exponentially. The Diabetic Foot Ulcer (DFU) epidemic increase in US Veteran Diabetes population due to poor clinical management is substantially greater than the civilian Medicare population resulting in an alarming LLA rate which is largely unnecessary. 

EZTREK® Novel Diabetic Foot-Ulcer Treatment - White Paper

It is well documented that diabetic patients have impaired delta-6 desaturase (D6D) metabolic pathways from impaired insulin production. In particular, this metabolic defect causes a poor anti-inflammatory response in Type I patients. Even with insulin therapy, the pathway is still deficient. Type II patients also have significant impairment of D6D activity. Diabetic foot ulcer (DFU) wound healing is impaired

Dr. Oscar Barreto DPM, NP, FACFAS
Private Clinical Study - EZTREK®

Five Clinical Case Studies involving Diabetic Foot Ulcers

2016 Chronic Wound Healing -
A Case Series study with an ingestible, calibrated formulation of PLANT-BASED LIPIDs (the adjuvant) at a University Wound Healing & Hyperbaric Center has been completed. (PEOs)

With all 14 patients taken as a group for statistical analysis, both wound surface area and wound volume statistically improved (decreased) with the PEO adjuvant. The magnitude of the effect was significant, and the percentage of the population it worked in was also significant.

Chronic Wound / Diabetic Ulcer Healing / Surgical Healing: A New Plant-Based Treatment Clinically Effective in Just 30 Days
TOWNSEND LETTER - APRIL 2016

Just 30 Days to Clinical Effectiveness in Healing Diabetic Ulcers and Underlying Pathophysiologic Disorders, Increasing Blood Flow, and Improving Surgical Outcomes with Case Studies

Pressure Ulcer Whitepaper:

EZTREK® – LIPID BASED ORAL MEDICATION FOR DERMAL WOUND HEALING 

$50B per year is spent on wound care. Chronic diabetic foot ulcers (DFUs) alone represent a substantial financial burden to the health care system costing up to $13B per year.  Both hospital costs and lengths of stay are significantly higher for military patients who develop pressure ulcers during hospitalization – more than $50,000 per patient and $1.5B annually. (2006)  
Copyrights 2024 | All Rights Reserved | Oxygen4life.com | Oxygen4lifeinc.com | Oxygen4Life Inc™
PRIVACY POLICY -  TERMS & CONDITIONS - BLOG
These statements have not been evaluated by the Food and Drug Administration. These products and statements are not intended to diagnose, treat, cure or prevent any disease or illness. These statements should not be taken as medical advice, you should always consult your doctor before making any health changes, decisions and/or drawing any health conclusions. 

This site is not a part of the Facebook website or Facebook Inc. Additionally, This site is NOT endorsed by Facebook in any way. FACEBOOK is a trademark of FACEBOOK, Inc.
Oxygen4Life, Inc. is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Title III of the JOBS Act and Regulation CF. A copy of the Form C that forms a part of the Offering Statement may be obtained from: Form C

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 105 Maxess Road, Suite 124, Melville, NY 11747, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA's BrokerCheck. DealMaker Securities LLC does not make investment recommendations. DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer. DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor's documentation for this investment. DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing. DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself. Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

Attributes:

CUSTOM JAVASCRIPT / HTML
Oxygen4Life, Inc. is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Title III of the JOBS Act and Regulation CF. A copy of the Form C that forms a part of the Offering Statement may be obtained from: Form C

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Any past performance described is not indicative of future results. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.


DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 4000 Eagle Point Corporate Drive, Suite 950, Birmingham, AL 35242, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA's BrokerCheck. 

DealMaker Securities LLC does not make investment recommendations.

DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer.

DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor’s documentation for this investment.

DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing.

DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself.

 Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

This website contains forward-looking statements. These statements may include the words “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate”, “project”, “will”, “may”, “targeting” and similar expressions as well as statements other than statements of historical facts including, without limitation, those regarding the financial position, business strategy, plans, targets and objectives of the management of Oxygen4Life, Inc. for future operations (including development plans and objectives). Such forward-looking statements involve known and unknown risks, uncertainties and other important factors which may affect the Company's ability to implement and achieve the economic and monetary policies, budgetary plans, fiscal guidelines and other development benchmarks set out in such forward-looking statements and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future policies and plans and the environment in which the Company will operate in the future. Furthermore, certain forward-looking statements are based on assumptions or future events which may not prove to be accurate, and no reliance whatsoever should be placed on any forward-looking statements in this presentation. The forward-looking statements in this website speak only as of the date of the Company's initial Form C, and the Company expressly disclaims to the fullest extent permitted by law any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.